Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15006984 | 0.91 | GPR119 (0.38) | GPR119CHEK2MAPK1CHRM2CHRM1 | |
| SCHEMBL10139212 | 0.90 | CHRM2 (0.38) | GPR119CHRM2CHRM1CHRM3 | |
| SCHEMBL15024919 | 0.88 | GPR119 (0.37) | GPR119CHRM2CHRM1CHRM3HDAC1 | |
| SCHEMBL15006940 | 0.87 | CHRNB2 (0.43) | CHEK2CHRNB2CHKAHDAC1 | |
| SCHEMBL15024744 | 0.87 | WNT3A (0.41) | GPR119CHRM2CHRM1CHRM3HDAC1 | |
| SCHEMBL15006726 | 0.86 | CHRNB2 (0.43) | CHRM2CHRM1CHRM3CHRNB2 | |
| SCHEMBL10138721 | 0.86 | UCHL1 (0.36) | GPR119MAPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL10138718 | 0.86 | CHRNB2 (0.36) | GPR119CHRM2CHRM1CHRM3CHRNB2 | |
| SCHEMBL10139708 | 0.86 | CHEK2 (0.42) | GPR119CHEK2CHRNB2 | |
| SCHEMBL10138669 | 0.86 | CHRM2 (0.36) | GPR119CHRM2CHRM1CHRM3CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606052-B1 | NICOTINIC RECEPTOR COMPOUNDS | RES TRIANGLE INST (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9284322-B2 | Nicotinic receptor compounds | RESEARCH TRIANGLE INSTITUTE (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150152119-A1 | NICOTINIC RECEPTOR COMPOUNDS | RES TRIANGLE INST (US) | 2015-06-04 | — | — | US | disclosed |
| WO-2012024615-A1 | NICOTINIC RECEPTOR COMPOUNDS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152119-A1 | NICOTINIC RECEPTOR COMPOUNDS | CHRNG, CHRNA7, CHRNA2 | GPR119 49/4885KIT 3062/4885CHEK2 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.